Endocrinology

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed islet cell transplant for the treatment of chronic pancreatitis.

The phase 1/2 trial of VX880 remains on clinical hold in the US.

Investigators from Seattle Children’s Hospital found that engineered T-cell regulatory products demonstrated significant suppression of effector T cells.

Investigators in Ukraine share data on the safety and efficacy of autologous mesenchymal stem cell administration for type 2 diabetes complications under the hypothesis that success is dependent on the administration route and quality of the autologous MSC population.

The company reports positive data from first 2 patients dosed, but the agency determined there is insufficient information to support dose escalation.

The Director of the Islet Transplant Program at the University of Alberta discussed the implantable VC-02 device's success in type 1 diabetes.

The reprioritization comes as the SIG-001 program remains on clinical hold after scarred and inviable cell spheres were observed in a treated patient.

The patient’s daily insulin requirement went from 34 units a day at baseline to 2.9 units a day 90 days after treatment.

An interim analysis has met prespecified safety and efficacy checkpoints.

Both Vertex and Arbor are adding to their list of gene and cell therapy partnerships with the announcement.

Study examining the role of IL-17A in patients with diabetes.

Selected abstracts from the American Diabetes Association's 80th Scientific Sessions discuss when to add injectable therapy, how patients who switched to semaglutide lost more weight and gained glycemic control, and offered results from an early-phase study on a monoclonal antibody that may preserve B-cell function.

A biomarker for pancreatic precursor cells might give researchers a shortcut to create insulin-producing beta cells that can be transplanted into patients with type 1 diabetes.

The Sanford Project: T-Rex Study has reached its midway point through a Phase II, fast-tracked trial.

Non-viral gene therapy can temporarily reduce painful diabetic neuropathy, according to research from Northwestern Medicine.

A novel treatment method called stem cell educator therapy appears to reverse the effects of type 1 diabetes, researchers at the University of Illinois at Chicago and colleagues in China report.